For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...
BOSTON, Nov. 13, 2024 /PRNewswire/ -- Servier today announced that it will present data at the Annual Meeting for the ...
Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax Failure – - 50% Response Rate at the Selected Dose Level of 30 ...
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company ...
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place Dec. 7-10 in San Diego. In an oral presentation, Lilly will report results from the ...
today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA. IN8bio is a ...
Company to host webcast on December 9, 2024 at 8:00am ET/5:00am PTWALTHAM, Mass. and BOULDER, Colo., Nov. 05, 2024 (GLOBE ...
For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback